文献速递瓣膜病与结构性心脏病

DEDICATE-DZHK6试验:主动脉瓣狭窄经导管或外科治疗的性别特异性结局

Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial.
PubMed 文献 · Eur Heart J · 2026-01-01

DEDICATE-DZHK6试验的预设描述性亚组分析,纳入1394例低至中危重度主动脉瓣狭窄患者(43.3%女性),比较TAVI与SAVR的性别特异性结局。女性TAVI组1年全因死亡或卒中为5.2% vs SAVR组11.5%(HR 0.46; 95%CI 0.25-0.82),男性为5.4% vs 9.0%(HR 0.61; 95%CI 0.35-1.03)。TAVI在女性和男性中主要结局均不劣于SAVR,TAVI组事件率更低;女性无论治疗方式早期并发症风险较高,SAVR后卒中风险增加。

要点

  • 女性TAVI组1年全因死亡或卒中5.2% vs SAVR组11.5%,HR 0.46(95%CI 0.25-0.82)。
  • 男性TAVI组1年全因死亡或卒中5.4% vs SAVR组9.0%,HR 0.61(95%CI 0.35-1.03)。
  • 女性SAVR后卒中风险增加(2.6% vs 6.2%,HR 0.43; 95%CI 0.18-0.93)。

核心结论

  • 在低至中危重度主动脉瓣狭窄患者中,女性和男性TAVI主要结局均不劣于SAVR,TAVI组事件率更低。
  • 女性无论接受TAVI或SAVR早期并发症风险均较高,且SAVR后卒中风险增加。

研究设计与样本

  • DEDICATE-DZHK6试验的预设描述性亚组分析,共纳入1394例低至中危重度主动脉瓣狭窄患者,其中女性占43.3%。
  • 比较分配至TAVI或SAVR患者的性别特异性特征和结局,主要终点为1年全因死亡或卒中。

主要发现

  • 女性年龄大于男性(74.8 ± 4.6岁 vs 74.2 ± 4.2岁,P = .020),手术风险更高(STS评分中位数2.1% vs 1.5%,P < .001)。
  • 女性1年全因死亡或卒中:TAVI组5.2% vs SAVR组11.5%(HR 0.46; 95%CI 0.25-0.82)。
  • 男性1年全因死亡或卒中:TAVI组5.4% vs SAVR组9.0%(HR 0.61; 95%CI 0.35-1.03)。
  • 女性1年全因死亡:TAVI组2.6% vs SAVR组6.7%(HR 0.41; 95%CI 0.17-0.90);男性:2.6% vs 5.9%(HR 0.44; 95%CI 0.20-0.88)。
  • 女性1年卒中:TAVI组2.6% vs SAVR组6.2%(HR 0.43; 95%CI 0.18-0.93);男性:3.1% vs 3.6%(HR 0.89; 95%CI 0.41-1.90)。

关键数值与推荐

  • 女性TAVI组1年全因死亡或卒中5.2%,SAVR组11.5%,HR 0.46(95%CI 0.25-0.82)。
  • 男性TAVI组1年全因死亡或卒中5.4%,SAVR组9.0%,HR 0.61(95%CI 0.35-1.03)。
  • 女性SAVR后1年卒中6.2% vs TAVI后2.6%,HR 0.43(95%CI 0.18-0.93)。

临床怎么用

  • 对低至中危重度主动脉瓣狭窄女性患者,TAVI在1年全因死亡或卒中方面不劣于SAVR且事件率更低。
  • 女性患者选择SAVR时需关注较高的早期并发症和卒中风险。
  • 男性患者TAVI同样不劣于SAVR,但主要结局HR的95%CI上限超过1。

局限性

  • 本研究为预设描述性亚组分析,非效能检验的性别交互作用分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Aortic stenosis may be managed differently in women and men, but evidence remains limited. Sex-specific characteristics and outcomes of low- to intermediate-risk patients assigned to transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) from the DEDICATE-DZHK6 trial are described. METHODS: The DEDICATE-DZHK6 trial demonstrated non-inferiority for the primary outcome of all-cause death or stroke at 1 year. Sex-specific effects were evaluated in this predefined descriptive subgroup analysis. RESULTS: A total of 1394 patients (43.3% women) were included. Women were older (women: 74.8 ± 4.6 years vs men: 74.2 ± 4.2 years, P = .020) and at higher operative risk [median Society of Thoracic Surgeons risk score 2.1% (1.5-2.7) vs 1.5% (1.0-2.2), P < .001]. All-cause death or stroke at 1 year was 5.2% in the TAVI vs 11.5% in the SAVR group [hazard ratio (HR) 0.46; 95% confidence interval (CI) 0.25-0.82] in women and 5.4% vs 9.0% (HR 0.61; 95% CI 0.35-1.03) in men. At 1 year after TAVI vs SAVR, all-cause death occurred in 2.6% vs 6.7% (HR 0.41; 95% CI 0.17-0.90) in women and 2.6% vs 5.9% (HR 0.44; 95% CI 0.20-0.88) in men. Stroke occurred in 2.6% vs 6.2% (HR 0.43; 95% CI 0.18-0.93) in women and 3.1% vs 3.6% (HR 0.89; 95% CI 0.41-1.90) in men. CONCLUSIONS: Among patients with severe aortic stenosis at low to intermediate risk, TAVI was non-inferior to SAVR for the primary outcome in women and men with lower event rates in patients assigned to TAVI. Women were at particular risk for early complications irrespective of the assigned treatment and at increased stroke risk after SAVR.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bleiziffer S, Leuschner F, Rudolph TK, et al. Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. Eur Heart J. 2026. PMID: 40900118. doi:10.1093/eurheartj/ehaf519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。